Table 1.
□ | Consider SLNB for all invasive breast cancer and cases of DCIS undergoing mastectomy |
□ | Utilize dual tracer (blue dye and radiocolloid) to optimize identification and reduce false negative rates, especially following neoadjuvant therapy, prior breast/axillary surgery or in patients with elevated BMI |
□ | Consider IV prophylaxis if blue dye utilized |
□ | Inject blue dye around tumor periphery, at the palpable edge of the biopsy cavity, or into the subareolar plexus |
□ | Inject radiocolloid peritumorally, intradermally, or into the subareolar plexus |
□ | Avoid injection into the tumor itself or into a seroma cavity |
□ | Consider lower dose or subareolar injection for tumors located in the axillary tail |
□ | Massage breast can be performed |
□ | Remove any suspicious palpable nodes |
Abbreviations: SLNB=sentinel lymph node biopsy; DCIS=ductal carcinoma in situ; BMI=body mass index; IV=intravenous